# Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

> **NCT00529113** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 33 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Pancreatic Cancer

## Interventions

- **DRUG:** Bardoxolone methyl
- **DRUG:** Bardoxolone methyl
- **DRUG:** Bardoxolone methyl
- **DRUG:** Bardoxolone methyl
- **DRUG:** Bardoxolone methyl
- **DRUG:** Bardoxolone methyl
- **DRUG:** Bardoxolone methyl
- **DRUG:** Gemcitabine
- **DRUG:** Placebo
- **DRUG:** Bardoxolone methyl

## Key facts

- **NCT ID:** NCT00529113
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09-30
- **Primary completion:** 2009-11-01
- **Final completion:** 2009-11-01
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** To pursue other indications
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529113, "Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00529113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*